AD 301
Alternative Names: AD-301Latest Information Update: 08 Aug 2024
At a glance
- Originator Addpharma
- Class Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis
Most Recent Events
- 08 Aug 2024 AD 301 is still in phase I development in Non-alcoholic-steatohepatitis in South Korea (Addpharma pipeline, August 2024)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis in South Korea
- 17 Dec 2020 AD 301 is available for licensing as of 17 Dec 2020. http://www.addpharma.co.kr/